25 April 2018

Blog by Anouck Kluytmans, researcher in early health technology assessment methodology at the Department for Health Evidence.

Accompanied by four lively examples, our Radboudumc proudly presents her vision on healthcare of the future. Personalized and innovative; that is how we’ll become a leading force in sustainable, innovative, and affordable healthcare. In our enthusiasm we seem to be overlooking that these noble causes are often at odds with one another.
 
An academic medical network with regard for the individual patient and innovation that leads us into the future – who could disagree? After all, who would like to be treated a dime a dozen using last century’s technology? The vision of the Radboudumc strongly appeals to our intuition. New is better. Or is it?
 
Perhaps it’s in our nature? We’re so good at attracting innovation – and so poorly equipped to resist. Indeed, patients may punish our institution when we neglect to hop the next big robotics train, or when we bravely disinvest in technology that turned out to be more than we bargained for. Once innovation enters our doors, vested interests and psychological biases will keep it there.
 
In my field of health technology assessment there is emerging awareness that the promise of innovation is limited. To be more precise, the value of innovation is limited by what we’re already achieving in healthcare today and by the constraints in our resources.
 
Mine is not a plea to ignore the future and change nothing. Rather, there’s hard work ahead of us in finding out what and how we want to change first. We find ourselves amidst a wave of innovation, each one more promising than its predecessor. Time and again we see the perfect novel solution to a problem that does not really exist. Impressive, high-level technology whose added value to the real-world patient is unclear at best. At an incremental price to our already overburdened budget, of course, stressing the accessibility of our healthcare system in the future. What I think we need and what I missed so much, is to take that one step back that allows us to reflect.
 
Before asking for solutions we should focus on identifying problems and needs. Where are the biggest windows of opportunity? What kind of innovation do we need? Being brave enough to make choices is one of Radboudumc’s strengths I’ve been missing in this recent strategy acceleration.
 
Innovation, sustainability, and affordability is a challenging triangle to navigate. Keeping the balance requires a priori critical evaluation of which innovations to pursue and why. We need complex, scary, real-world decision-making before swinging our doors wide open.
 
Anouck Kluytmans, MSc
member of the theme Healthcare improvement science
 

Related news items


Frank Walboomers 25-years work anniversary at Radboudumc

17 September 2020

Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.

read more

Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes

17 September 2020

Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.

read more

Annette Schenck appointed professor of Translational Genetics

17 September 2020

Annette Schenck has been appointed professor of Translational Genetics at the department of Neurodevelopmental disorders, with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.

read more

Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients

17 September 2020

Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.

read more

Radboudumc does large-scale research on systemic sclerosis

10 September 2020

In rare diseases, such as systemic sclerosis, it’s often difficult to conduct large-scale research. Rheumatologist Madelon Vonk has managed to follow enough patients with systemic sclerosis for years. The results of her research have been published in BMJ Annal of the Rheumatic Diseases.

read more